Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 291

Sort by

Sort Order Select

Journal Articles

Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses

Blood blood.2024024582.

https://doi.org/10.1182/blood.2024024582

Published: 2024

Includes: Supplemental data

Journal Articles

Cost per Responder Analysis of Patients with Lenalidomide-Refractory Multiple Myeloma Who Received Cilta-Cel from the Cartitude-4 Trial

Doris K. Hansen, Xiaoxiao Lu, Omar Castaneda, Sonja Sorensen, Saad Z Usmani, Eileen Zhang, Stephen Huo, Sundar Jagannath

Blood (2023) 142 (Supplement 1): 5083.

https://doi.org/10.1182/blood-2023-181179

Published: 2023

Journal Articles

Mezigdomide Treatment in Relapsed-Refractory Myeloma Patients Shifts Bone Marrow NK and T Cell Populations from Exhaustion to Activation

Lucia Y Chen, Oliver Van Oekelen, Michael Amatangelo, Tracy T. Chow, Bhaskar Upadhyaya, Alessandro Lagana, Geoffrey Kelly, Seunghee Kim-Schulze, Adolfo Aleman, Antonina Kurtova, Sarah Gooding, Sundar Jagannath, Erin Flynt, Anita K. Gandhi, Udo Oppermann, Anjan Thakurta, Samir Parekh

Blood (2023) 142 (Supplement 1): 4686.

https://doi.org/10.1182/blood-2023-187748

Published: 2023

Journal Articles

Multimodal Single-Cell Transcriptomic and Proteomic Correlatives of Patients Outcomes Following Anti-BCMA Cellular Therapy with Ciltacabtagene Autoleucel (Cilta-cel) in Relapsed Multiple Myeloma

Blood (2023) 142 (Supplement 1): 93.

https://doi.org/10.1182/blood-2023-186395

Published: 2023

Journal Articles

Durable MRD and Imaging-Negative Remission ≥ 5 Years Post-Therapy Predicts Long-Term Progression-Free Survival in Multiple Myeloma Patients - a Single-Center Observational Study

Lucia Y Chen, Santiago Thibaud, Ajai Chari, Joshua Richter, Hearn Jay Cho, Larysa J Sanchez, Cesar Rodriguez, Adriana C Rossi, Shambavi Richard, Samir Parekh, Sundar Jagannath

Blood (2023) 142 (Supplement 1): 1998.

https://doi.org/10.1182/blood-2023-190368

Published: 2023

Journal Articles

Clinical Outcomes in Real-World Patients (RW) with Triple-Class Exposed (TCE) Relapsed/Refractory Multiple Myeloma (RRMM): A Retrospective Study Using Electronic Health Records from Flatiron Health and COTA Vantage Databases

Hans C. Lee, Sundar Jagannath, Devender Dhanda, Teofilia Acheampong, Pallavi Patwardhan, Thomas S. Marshall, Suvina Amin, Tao Gu, Sikander Ailawadhi

Blood (2023) 142 (Supplement 1): 3775.

https://doi.org/10.1182/blood-2023-173661

Published: 2023

Journal Articles

Idecabtagene Vicleucel (ide-cel) Versus Standard (std) Regimens in Patients (pts) with Triple-Class-Exposed (TCE) Relapsed and Refractory Multiple Myeloma (RRMM): Updated Analysis from KarMMa-3

Blood (2023) 142 (Supplement 1): 1028.

https://doi.org/10.1182/blood-2023-178933

Published: 2023

Journal Articles

Cellular Mechanisms Associated with Suboptimal Immune Responses to Sars-Cov-2 Bivalent Booster Vaccination in Patients with Multiple Myeloma

Adolfo Aleman, Morgan Van Kesteren, Ariel Kogan Zajdman, Komal Srivastava, Lucia Y Chen, Bhaskar Upadhyaya, Jessica Nardulli, Kseniya Serebryakova, Katerina Kappes, Hayley Jackson, Charles Gleason, Oliver Van Oekelen, Carlos Cordon-Cardo, Ania Wajnberg, Florian Krammer, Miriam Merad, Sundar Jagannath, Viviana Simon, Samir Parekh

Blood (2023) 142 (Supplement 1): 1984.

https://doi.org/10.1182/blood-2023-187260

Published: 2023

Journal Articles

Treatment Outcomes and Prognostic Factors with Lenalidomide, Bortezomib, and Dexamethasone (RVd) Alone Versus Rvd Plus Autologous Stem Cell Transplantation (ASCT) in African American (AA) Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) in the Determination Phase 3 Trial

Blood (2023) 142 (Supplement 1): 4762.

https://doi.org/10.1182/blood-2023-181032

Published: 2023

Journal Articles

Health-Related Quality of Life (HRQoL) Among Patients with Triple-Class Exposed Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Linvoseltamab in Linker-MM1: Interim Assessment up to 36 Weeks of Treatment

Blood (2023) 142 (Supplement 1): 3359.

https://doi.org/10.1182/blood-2023-179170

Published: 2023

Journal Articles

Immune Dynamics Associated with Patient Outcomes Identified By Multimodal Single-Cell Analysis in Multiple Myeloma Patients Receiving Talquetamab Monotherapy

Blood (2023) 142 (Supplement 1): 1927.

https://doi.org/10.1182/blood-2023-185308

Published: 2023

Journal Articles

Clinical Outcomes of Subsequent Therapies in Patients with Relapsed/Refractory Multiple Myeloma Following Talquetamab Treatment: Analyses from the Phase 1/2 MonumenTAL-1 Study

Blood (2023) 142 (Supplement 1): 2007.

https://doi.org/10.1182/blood-2023-182330

Published: 2023

Journal Articles

Early and Consistent CRS Detection Using Wearable Device for Remote Patient Monitoring Following CAR-T Therapy in Relapsed/Refractory Multiple Myeloma (RRMM): Early Results of an Investigator-Initiated Trial

Blood (2023) 142 (Supplement 1): 1007.

https://doi.org/10.1182/blood-2023-181936

Published: 2023

Journal Articles

Outcomes after CAR T Cells in Multiple Myeloma Patients with Extramedullary and Paramedullary Disease

Darren Pan, Tarek H. Mouhieddine, Weijia Fu, Erin Moshier, Samir Parekh, Sundar Jagannath, Adriana C Rossi, Joshua Richter, Cesar Rodriguez, Larysa J Sanchez, Santiago Thibaud, Hearn Jay Cho, Shambavi Richard

Blood (2023) 142 (Supplement 1): 1006.

https://doi.org/10.1182/blood-2023-177749

Published: 2023

Journal Articles

Inflammatory Marker Levels, Age, Race and Prior Treatment Burden Independently Predict Delayed Hematologic Recovery after BCMA-Directed CART Therapy in Multiple Myeloma

Santiago Thibaud, Jerrel Catlett, Saoirse Bodnar, MD Babu Mia, Ajai Chari, Joshua Richter, Hearn Jay Cho, Larysa J Sanchez, Cesar Rodriguez, Adriana C Rossi, Sundar Jagannath, Shambavi Richard, Samir Parekh

Blood (2023) 142 (Supplement 1): 2002.

https://doi.org/10.1182/blood-2023-190772

Published: 2023

Journal Articles

Heterogeneity in Access and Toxicity Management of Commercially Available BCMA-Directed CAR-T and Bispecific T-Cell Engager Therapy Among the International Myeloma Community

Blood (2023) 142 (Supplement 1): 7248.

https://doi.org/10.1182/blood-2023-184710

Published: 2023

Journal Articles

Bendamustine Bridging Versus Standard of Care Chemotherapy on Toxicity Profile for Multiple Myeloma Patients Undergoing CAR T Cell Therapy

Yan Leyfman, Sridevi Rajeeve, Tianxiang Sheng, Marcio Diniz, Shambavi Richard, Sundar Jagannath, Adriana C Rossi

Blood (2023) 142 (Supplement 1): 6861.

https://doi.org/10.1182/blood-2023-181420

Published: 2023

Journal Articles

Patterns of Response to 200 Mg Linvoseltamab in Patients with Relapsed/Refractory Multiple Myeloma: Longer Follow-Up of the Linker-MM1 Study

Blood (2023) 142 (Supplement 1): 4746.

https://doi.org/10.1182/blood-2023-177968

Published: 2023

Journal Articles

Inflammatory Biomarkers and Outcomes in Multiple Myeloma Patients after CAR T-Cell Therapy

Darren Denjay Pan, Tarek H. Mouhieddine, Weijia Fu, Erin Moshier, Samir Parekh, Sundar Jagannath, Adriana C Rossi, Hearn Jay Cho, Joshua Richter, Larysa J Sanchez, Santiago Thibaud, Cesar Rodriguez, Shambavi Richard

Blood (2023) 142 (Supplement 1): 92.

https://doi.org/10.1182/blood-2023-188310

Published: 2023

Journal Articles

Confirmed Pathogenic Germline Variants in Cancer Predisposition Genes Incidentally Detected in Somatic Genomic Profiling of Multiple Myeloma Patients

Santiago Thibaud, William Genthe, Saoirse Bodnar, Alessandro Lagana, Jane Houldsworth, Ajai Chari, Adriana C Rossi, Cesar Rodriguez, Larysa J Sanchez, Shambavi Richard, Joshua Richter, Kenan Onel, Sundar Jagannath, Tehilla Brander, Samir Parekh

Blood (2023) 142 (Supplement 1): 534.

https://doi.org/10.1182/blood-2023-190878

Published: 2023

NARROW

Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses

Cost per Responder Analysis of Patients with Lenalidomide-Refractory Multiple Myeloma Who Received Cilta-Cel from the Cartitude-4 Trial

Mezigdomide Treatment in Relapsed-Refractory Myeloma Patients Shifts Bone Marrow NK and T Cell Populations from Exhaustion to Activation

Multimodal Single-Cell Transcriptomic and Proteomic Correlatives of Patients Outcomes Following Anti-BCMA Cellular Therapy with Ciltacabtagene Autoleucel (Cilta-cel) in Relapsed Multiple Myeloma

Durable MRD and Imaging-Negative Remission ≥ 5 Years Post-Therapy Predicts Long-Term Progression-Free Survival in Multiple Myeloma Patients - a Single-Center Observational Study

Clinical Outcomes in Real-World Patients (RW) with Triple-Class Exposed (TCE) Relapsed/Refractory Multiple Myeloma (RRMM): A Retrospective Study Using Electronic Health Records from Flatiron Health and COTA Vantage Databases

Idecabtagene Vicleucel (ide-cel) Versus Standard (std) Regimens in Patients (pts) with Triple-Class-Exposed (TCE) Relapsed and Refractory Multiple Myeloma (RRMM): Updated Analysis from KarMMa-3

Cellular Mechanisms Associated with Suboptimal Immune Responses to Sars-Cov-2 Bivalent Booster Vaccination in Patients with Multiple Myeloma

Treatment Outcomes and Prognostic Factors with Lenalidomide, Bortezomib, and Dexamethasone (RVd) Alone Versus Rvd Plus Autologous Stem Cell Transplantation (ASCT) in African American (AA) Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) in the Determination Phase 3 Trial

Health-Related Quality of Life (HRQoL) Among Patients with Triple-Class Exposed Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Linvoseltamab in Linker-MM1: Interim Assessment up to 36 Weeks of Treatment

Immune Dynamics Associated with Patient Outcomes Identified By Multimodal Single-Cell Analysis in Multiple Myeloma Patients Receiving Talquetamab Monotherapy

Clinical Outcomes of Subsequent Therapies in Patients with Relapsed/Refractory Multiple Myeloma Following Talquetamab Treatment: Analyses from the Phase 1/2 MonumenTAL-1 Study

Early and Consistent CRS Detection Using Wearable Device for Remote Patient Monitoring Following CAR-T Therapy in Relapsed/Refractory Multiple Myeloma (RRMM): Early Results of an Investigator-Initiated Trial

Outcomes after CAR T Cells in Multiple Myeloma Patients with Extramedullary and Paramedullary Disease

Inflammatory Marker Levels, Age, Race and Prior Treatment Burden Independently Predict Delayed Hematologic Recovery after BCMA-Directed CART Therapy in Multiple Myeloma

Heterogeneity in Access and Toxicity Management of Commercially Available BCMA-Directed CAR-T and Bispecific T-Cell Engager Therapy Among the International Myeloma Community

Bendamustine Bridging Versus Standard of Care Chemotherapy on Toxicity Profile for Multiple Myeloma Patients Undergoing CAR T Cell Therapy

Patterns of Response to 200 Mg Linvoseltamab in Patients with Relapsed/Refractory Multiple Myeloma: Longer Follow-Up of the Linker-MM1 Study

Inflammatory Biomarkers and Outcomes in Multiple Myeloma Patients after CAR T-Cell Therapy

Confirmed Pathogenic Germline Variants in Cancer Predisposition Genes Incidentally Detected in Somatic Genomic Profiling of Multiple Myeloma Patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only